RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
NKT 激动剂-抗原偶联物作为癌症疫苗
英文原题：NKT Agonist-Antigen Conjugates as Cancer Vaccines.
查看英文原题
NKT Agonist-Antigen Conjugates as Cancer Vaccines.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自然杀伤T（NKT）细胞是一群具有先天免疫样特征的T细胞，能够增强固有免疫和适应性免疫应答。将NKT细胞激动剂与抗原共同递送，可为树突状细胞和B细胞等抗原提呈细胞提供分子信号，从而促进强效的抗原特异性适应性免疫应答。因此，尤其是在过去十年中，已有大量依赖NKT细胞的疫苗疗法被开发出来，其中许多整合了肿瘤抗原。在本综述中，我们总结了将NKT细胞激动剂与抗原进行化学偶联的研究，该策略作为一种有效的激动剂-抗原共同递送方式，可驱动抗肿瘤应答。
展开英文摘要原文
Natural killer T (NKT) cells are a population of innate-like T cells capable of enhancing both innate and adaptive immune responses. Co-delivering an NKT cell agonist and antigen can provide molecular signals to antigen-presenting cells, such as dendritic and B cells, that facilitate strong antigen-specific adaptive immune responses.
Accordingly, there has been a significant number of developmental NKT cell-dependent vaccine therapies developed, particularly in the last decade, with many incorporating cancer antigens. In this review, we summarize studies that chemically conjugate the NKT cell agonist and antigen as an effective strategy for agonist-antigen co-delivery to drive antitumor responses.
论文信息
- 作者
- Compton BJ、Painter GF
- 第一作者单位
- Ferrier Research Institute, Victoria University of Wellington, Lower Hutt 5010, New Zealand.New Zealand
- 通讯作者单位
- Ferrier Research Institute, Victoria University of Wellington, Lower Hutt 5010, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Auckland 1010, New Zealand.New Zealand
- 文献类型
- 综述
- 期刊
- Critical reviews in oncogenesis2024
- 原文标识
- PubMed 38421711 · DOI 10.1615/CritRevOncog.2023049091